PMID- 35915689
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220803
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 6
DP  - 2022 Jun
TI  - 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief 
      Review.
PG  - e26402
LID - 10.7759/cureus.26402 [doi]
LID - e26402
AB  - The Food and Drug Administration (FDA) granted breakthrough therapy status to 
      3,4-methyl​enedioxy​methamphetamine-assisted therapy (MDMA-AT) in 2017 due to 
      preliminary evidence supporting its efficacy and safety in treating 
      post-traumatic stress disorder (PTSD). A series of six phase-II clinical trials 
      studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose 
      participants no longer met the diagnosis of PTSD after two MDMA sessions, 
      compared to 23% in the control group. In the first phase-III clinical trial, 67% 
      no longer met the criteria for PTSD after three sessions. The effects are 
      durable, with 67% no longer diagnosable after one year and 74% at nearly four 
      years. The MDMA-AT is being fast-tracked for potential FDA approval by 2023. In 
      2021, Hawaii's Senate Bill 738 unsuccessfully proposed that psilocybin be removed 
      from the Schedule I controlled substances list due to its clinical efficacy for 
      major depressive disorder. Methyl​enedioxy​methamphetamine is also a Schedule I 
      controlled substance and has proven to be a treatment option that could 
      potentially benefit the people of Hawaii.
CI  - Copyright (c) 2022, Inouye et al.
FAU - Inouye, Ann
AU  - Inouye A
AD  - Psychology, Hawaii School of Professional Psychology, Honolulu, USA.
FAU - Wolfgang, Aaron
AU  - Wolfgang A
AD  - Psychiatry, Brooke Army Medical Center, San Antonio, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220628
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9337778
OTO - NOTNLM
OT  - hawaii
OT  - mdma-assisted psychotherapy
OT  - mdma-at
OT  - neurobiology
OT  - neuropsychology
OT  - psychedelics
OT  - psychoactive drug
OT  - trauma
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/08/03 06:00
MHDA- 2022/08/03 06:01
PMCR- 2022/06/28
CRDT- 2022/08/02 01:46
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/08/02 01:46 [entrez]
PHST- 2022/08/03 06:00 [pubmed]
PHST- 2022/08/03 06:01 [medline]
PHST- 2022/06/28 00:00 [pmc-release]
AID - 10.7759/cureus.26402 [doi]
PST - epublish
SO  - Cureus. 2022 Jun 28;14(6):e26402. doi: 10.7759/cureus.26402. eCollection 2022 
      Jun.